Podcasts

Episode 1 | Improving Survival In Oncogene Driven Lung Cancer

A conversation with Associate Professor Tom John and Professor Ben Solomon where they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing.

Improving Survival In Oncogene Driven Lung Cancer

Episode Summary

Join us for a conversation with internationally recognized Medical Oncologists and researchers, Prof Ben Solomon & A/Prof Tom John as they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing.

Oncogenes discussed include EGFR & osimertinib; ALK & brigatinib, alectinib, lorlatinib; ROS1 & crizotinib, entrectinib; KRAS & sotorasib; G12C; Exon20 insertions & poziotinib, amivantamab, RET & selpercatinib, pralcetinib. Also discussed – the importance of the move beyond single gene testing to panels and NGS is important to maximise turn-around times and the efficient utilization of clinical samples.

Show Hosts

This episode’s host are:

Prof Ben Solomon, Scientific Chair, TOGA; Medical Oncologist, Peter MacCallum Cancer
A/Prof Thomas John, Scientific Committee Chair, TOGA; Medical Oncologist, Peter MacCallum Cancer Centre

Play Episode 1 | Improving Survival In Oncogene Driven Lung Cancer

More Podcasts

72 – Dr Jazmin Eckhaus: Robotic Innovations and Ethics in Thoracic Surgery

Podcasts
July 31, 2026

Host A/Prof Mel Moore interviews Dr Jazmin Eckhaus, a practising surgeon in the subspecialty of thoracic surgery.

71 – Immunotherapy in Thoracic Cancers: Applying Broad IO Access Across Thoracic Malignancies

Podcasts
June 26, 2026

Host A/Prof Adnan Nagrial leads a panel discussing the clinical implications of the broad PBS listing of ipilimumab and nivolumab in Australia.

70 – Immunotherapy in Thoracic Cancers: From Indication-Based to Biology-Driven

Podcasts
June 19, 2026

Host A/Prof Deme Karikios leads a panel discussion focusing on the recent, groundbreaking broad PBS listing of certain immunotherapy agents in Australia.

69 – The Evolving Landscape of BRAF-Mutated NSCLC in Australia

Podcasts
June 5, 2026

Host A/Prof Rachel Roberts-Thomson leads a panel discussion focusing on the landscape of BRAF-mutated non-small cell lung cancer.

68 – Thymic Cancer: The Lesser-Known Thoracic Tumours

Podcasts
May 22, 2026

In this episode of TOGA's Conversations in Lung Cancer Research, host A/Prof Malinda Itchins, a medical oncologist and clinician researcher at Royal North Shore Hospital

67 – A/Prof Surein Arulananda: A Masterclass in Career Growth

Podcasts
May 8, 2026

In this episode, we welcome A/Prof Surein Arulananda, the interim Director of Medical Oncology and Thoracic Oncology Trials Lead at Monash Health.

Join our community – stay up to date with the latest research, TOGA news and events

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Contact

PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198

TOGA

Quicklinks

Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.